HER3 signaling and targeted therapy in cancer by Rosalin Mishra, Hima Patel, Samar Alanazi, Long Yuan, Joan T. Garrett

Get full text

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects by Rosalin Mishra, Hima Patel, Samar Alanazi, Mary Kate Kilroy, Joan T. Garrett

Get full text

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma by Hima Patel, Rosalin Mishra, Nour Yacoub, Samar Alanazi, Mary Kate Kilroy, Joan T. Garrett

Get full text

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels by Long Yuan, Rosalin Mishra, Hima Patel, Samar Alanazi, Xin Wei, Zhijun Ma, Joan T. Garrett

Get full text

Current Advances in the Treatment of BRAF-Mutant Melanoma by Hima Patel, Nour Yacoub, Rosalin Mishra, Aaron White, Long Yuan, Samar Alanazi, Joan T. Garrett

Get full text

HER3 Alterations in Cancer and Potential Clinical Implications by Mary Kate Kilroy, SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Samar Alanazi, Joan T. Garrett

Get full text

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. by Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett

Get full text

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces... by Rosalin Mishra, Long Yuan, Hima Patel, Aniruddha S. Karve, Haizhou Zhu, Aaron White, Samar Alanazi, Pankaj Desai, Edward J. Merino, Joan T. Garrett

Get full text